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that in mixed populations of neural pro-
genitors, such as those that typically arise
during neural differentiation of embryonic
stem cells, regionally fated progenitors
may be selectively sensitive to factor(s)
that shorten the cell cycle and enhance
self-renewal. Over several passages, a
significant increase in one population
relative to another may result. This obser-
vation may permit researchers to perform
negative and positive selection to enrich
specific progenitor subtypes. For exam-
ple, according to the Falk et al. study, ad-
dition of TGF-b to mixed forebrain/mid-
brain neurosphere cultures would favor
forebrain-derived relative to midbrain-
derived progenitors due to reduced
midbrain progenitor self-renewal. These
results also underscore the idea that cul-
ture conditions that appear to direct stem
cell differentiation toward a particular
lineage may, in fact, lead to the enrich-
ment of a specific population by differen-
tial expansion of a pre-existing progenitor
instead.
Several important questions, both de-
velopmental and practical, are raised by
the results of Falk et al. (2008). First, do
physiological or pathophysiological alter-
ations in TGF-b levels alter the relative
size of the midbrain? Second, do species
differences in the responses to or release
of TGF-b correlate with the relative size
of midbrain structures such as the supe-
rior and inferior colliculi? Third, are all
progenitors within the dorsal midbrain
equally capable of enhanced self-re-
newal upon removal of TGF-b signaling,
or are specific subsets of the population
sensitive to TGF-b? And fourth, are there
other region-specific signaling cascades
that might be manipulated in neural
stem cell cultures to selectively expand
particular progenitors? For example, do
populations with therapeutic potential,
such as forebrain or ventral midbrain
progenitors, exhibit differential sensitivity
to other factors that stimulate or inhibit
self-renewal? If so, it may be possible
in the future to select different neural
stem cell subtypes from mixed popula-
tions by taking advantage of definitive re-
gion-specific responses such as those
described by Falk et al.
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Cancer stem cells (CSCs) are a subpopulation of tumor cells that retain properties of tissue-specific stem
cells, including the ability to self-renew. In a recent article in Nature, Malanchi et al. (2008) identified a popu-
lation of CD34+ cells in epidermal tumors that require b-catenin signaling to maintain a CSC phenotype.Tissue-specific stem cells maintain
a strictly regulated balance between self-
renewal and differentiation to preserve
the stem cell pool and give rise to all the
cell lineages in the organ. Stemor progen-
itor cells may serve as cancer-initiating
cells, following deregulation of the self-re-
newal process (Wicha et al., 2006). It has
been hypothesized that cancer-initiating
stem cells give rise to cancer stem cells
(CSCs), although there is a lack of direct
evidence that these are the same cell pop-
ulation. CSCs are a subpopulation of cells
within tumors that retain stem cell proper-406 Cell Stem Cell 2, May 2008 ª2008 Elsevties, undergoing long-term self-renewal
and driving tumor growth by giving rise to
the differentiated cells that comprise the
majority of the tumor mass. CSCs have
been well-characterized in hematopoietic
tumors, where serial transplantation stud-
ies in immunocompromised mice demon-
strate that grafted CSCs give rise to tu-
mors that maintain the complexity of the
primary tumor. More recently, CSCs
have been identified in solid tumors in-
cluding breast, central nervous system,
prostate, colon, and pancreas (Ailles and
Weissman, 2007; Al-Hajj et al., 2003).ier Inc.Mammalian epidermis is a rapidly re-
newing tissue and is maintained by stem
cells that give rise to the differentiated lin-
eages of the interfollicular epidermis, se-
baceous glands, hair follicles, and sweat
glands. The bulge region of the murine
hair follicle contains a population of multi-
potent stem cells capable of giving rise to
all of the epithelial cell lineages within the
hair follicle during normal hair growth and
contributing transiently to the interfollicu-
lar epidermis in response to wounding.
Whereas most epidermal cells are lost
via a process of terminal differentiation,
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PreviewsFigure 1. Epidermal and Cutaneous Cancer Stem Cells
(A) Schematic of murine skin. CD34+ bulge keratinocytes are indicated in red.
(B) CD34+ CSCs initiate secondary tumors following engraftment, and b-catenin signaling is required to maintain epidermal tumors.stem cells are long-term tissue residents
capable of acquiring multiple genetic mu-
tations over time, which can ultimately
lead to tumor formation. There is convinc-
ing evidence that murine bulge stem cells
are particular targets for carcinogen-
mediated tumor initiation (Morris, 2000).
It has been suggested that phenotypi-
cally conserved stem and progenitor cell
markers may be inherited by CSCs from
the cell of origin, providing a stem cell
identifier shared by normal tissue and
multiple cancer histotypes that may arise
there. In the murine epidermis, one such
candidate marker is CD34, a cell-surface
marker that has been used to enrich for
multipotent stem cells from the hair follicle
bulge (Trempus et al., 2003) (Figure 1A).
Malanchi et al. (2008) have characterized
a subpopulation of CD34+ keratinocytes
in murine epidermal tumors induced by
chemical (DMBA/TPA) carcinogenesis.
The percentage of CD34+ keratinocytes
was increased in epidermal tumors (papil-
lomas and squamous cell carcinomas
[SCCs]) versus normal epidermis, al-
though it was not clearly demonstrated
whether these cells are progeny of pre-
existing CD34+ cells or de novo CD34-
expressing cells. However, the CD34+
population exhibited phenotypic charac-
teristics of bulge stem cells, including
expression of bulge markers and an
absence of the differentiation markerkeratin 10. Importantly, in contrast to
CD34 cells, a subpopulation of CD34+
cells were capable of giving rise to sec-
ondary and tertiary tumors that recapitu-
lated the original tumor phenotype upon
engraftment into immunocompromised
mice (Figure 1B). Taken together, these
results indicate that the CD34+ population
contains CSCs.
The canonical Wnt/b-catenin signaling
pathway has been implicated in maintain-
ing stem cell homeostasis in most epithe-
lial tissues including skin, mammary
gland, and intestine. Furthermore, dereg-
ulation of this pathway often leads to for-
mation of epithelial cancers (Reya and
Clevers, 2005). In the absence of active
Wnt signaling, intracellular b-catenin is
phosphorylated, targeting it for proteo-
lytic degradation. Activation of canonical
Wnt signaling inhibits this degradation,
allowing b-catenin to translocate to the
nucleus and form complexes with Tcf/
Lef family transcription factors to modu-
late expression of multiple genes. In the
skin, high levels of b-catenin lead to hair
growth, ectopic hair follicle formation
in transgenic mice (Silva-Vargas et al.,
2005), and the formation of pilomatriculo-
mas in both mice and man. In contrast,
inhibiting b-catenin blocks formation of
hair during development (Huelsken et al.,
2001) or disrupts growth of pre-existing
hair follicles in the adult. In addition,Cell Steb-catenin has been implicated in bulge
stem cell maintenance/activation.
In chemically induced skin tumors,
nuclear b-catenin was enriched in CD34+
versus CD34 tumor cells (Malanchi
et al., 2008), suggesting a potential func-
tional relevance for this pathway. More
importantly, deletion of b-catenin in es-
tablished tumors led to a reduction in the
percentage of CD34+ cells, and the tu-
mors regressed, as marked by extensive
terminal differentiation (Figure 1B). The
skin tumor regression phenotype was
recapitulated following b-catenin deletion
in another mouse skin tumor model
(TG.AC) that expresses activated H-Ras.
Taken together, these data suggest that
b-catenin is required for Ras-driven skin
tumorigenesis, although the mechanism
of CSC loss following b-catenin deletion
is not yet established. It should be noted
that a keratin 14 promoter was used to
target an inducible form of Cre recombi-
nase in these mouse models. Since this
promoter is active in all undifferentiated
epidermal keratinocytes, the modifica-
tions in tumor phenotype cannot be solely
attributed to deletion of b-catenin within
the CSC subpopulation.
Finally, Malanchi and colleagues
(Malanchi et al., 2008) provide evidence
that b-catenin signaling may be function-
ally relevant in human SCCs. Both nu-
clear b-catenin and expression of them Cell 2, May 2008 ª2008 Elsevier Inc. 407
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detected inmany human SCCs. Following
knockdown of b-catenin expression by
short hairpin RNA, tumor growth of human
SCC13 cell lines was reduced in xeno-
grafts, suggesting that b-catenin signaling
is required for tumorigenesis. However,
as noted by the authors, nuclear b-catenin
expression is not strictly a marker of
CSCs, and CD34 is not expressed in hu-
man SCCs, precluding a CSC analysis of
human tumors. In the human hair follicle,
CD34 immunoreactivity is found below
the bulge; however, there is no evidence
that this marker enriches for stem cells.
Several markers have been reported to
enrich for human interfollicular stem cells,
including high expression of b1 integrin,
high expression of a6 integrin (in combi-
nation with low levels of CD71), and
expression ofmelanoma-associatedchon-
droitin sulfate proteoglycan or Lrig1. In the
human hair follicle, CD200-positive bulge
cells have a high clonogenic-forming ca-
pacity in vitro, a characteristic associated
with stem cells (Ohyama et al., 2006).
Therefore, in future studies it will be usefulOpen Chromatin a
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scription in mouse embryonic stem
Hypertranscription may reflect the u
By several criteria, ESC nuclear DNA is
packaged in an unusual form of chromatin
that appears to be more ‘‘open’’ than that
in differentiated cells. Histones and non-
histone proteins exchange more rapidly,
i.e., are more loosely bound to DNA, in
ESCs (Meshorer et al., 2006), their consti-
tutive heterochromatin is more dispersed,
or at least less prominent microscopically
(Meshorer et al., 2006; Spivakov and
Fisher, 2007), and the positioning of genes
408 Cell Stem Cell 2, May 2008 ª2008 Elsevto determine whether any of these
markers identify CSCs within human epi-
dermal tumors.
In summary, Malanchi and colleagues
(Malanchi et al., 2008) elegantly demon-
strate that murine cutaneous tumors con-
tain a subpopulation of CSCs that can be
enriched by selection for the follicular
bulge cell surface marker, CD34. They
provide convincing evidence that b-cate-
nin signaling is required for growth of
murine squamous cell carcinomas, most
likely via the maintenance of CSCs, al-
though the mechanism by which this
occurs is still unclear. Finally, they dem-
onstrate that the Wnt/b-catenin pathway
also is activated in human malignant
SCCs. However, the challenge remains
to identify CSCs within human epidermal
tumors. These studies are reminiscent of
the role that the Wnt/b-catenin pathway
plays in modulating stem cell mainte-
nance and tumorigenesis in the intestinal
tract, suggesting that therapeutic inter-
ventions targeting this pathway may be
beneficial in multiple epithelial tissues
(Reya and Clevers, 2005).nd Hypertranscrip
Cells
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i et al. (2008) use tiling microarrays
cells (ESCs), including expression of
nusual ‘‘open’’ structure of ESC chr
and chromosome territories changes
markedly on ESC differentiation (Gia-
drossi et al., 2007). ESCs also exhibit
global enrichment of histone modifica-
tions associatedwith transcriptional activ-
ity as well as depletion of modifications
associated with silent chromatin (Spiva-
kov and Fisher, 2007). Meshorer, Misteli,
and colleagues (Efroni et al., 2008) now
provide further evidence for the open
structure of ESC chromatin and go on to
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to reveal genome-wide hypertran-
normally silent, noncoding regions.
omatin.
ask whether it might be associated with
altered transcription.
In their analyses, Efroni et al. (2008) uti-
lize whole-genome tiling arrays to com-
pare transcript levels in the R1 ESC line
to those present in their differentiated
progeny. In ESCs, transcription was de-
tected in intronic, intergenic, and exonic
regions, with over-threshold readings
from just over one-million probes. In con-
trast, the number of positive probes was
